PMID- 25639676
OWN - NLM
STAT- MEDLINE
DCOM- 20160105
LR  - 20150418
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 18
IP  - 2
DP  - 2015 Feb
TI  - Tolerogenic dendritic cells: role and therapeutic implications in systemic lupus 
      erythematosus.
PG  - 250-9
LID - 10.1111/1756-185X.12532 [doi]
AB  - Dendritic cells (DCs) are antigen presenting cells that activate T cells and 
      determine the outcome of immune response. In addition to their important function 
      in defense against pathogens, DCs are increasingly recognized as playing a 
      crucial role in the regulation of immune tolerance. Plasticity of DCs with 
      different maturity status and functions enable them to be exploited as potential 
      cell-based therapy to restore immune tolerance in autoimmune diseases. Various ex 
      vivo methods have been developed to generate stable tolerogenic DCs that are able 
      to induce and maintain regulatory T cell homeostasis. The beneficial effect of 
      tolerogenic DCs have been studied in murine autoimmune models with promising 
      results. Systemic lupus erythematosus (SLE) is a prototypic multi-systemic 
      autoimmune disease characterized by autoantibody production and deposition of 
      immune complexes in organs. There are evidences that dysregulated DCs play a 
      pivotal role in the initiation and perpetuation of lupus disease. Peripheral 
      blood monocytes in SLE patients were found to have active phenotype with 
      accelerated differentiation into DCs efficient in antigen presentation. 
      Plasmacytoid DCs in SLE patients produce high levels of interferon-alpha, the 
      signature cytokine of this disease, that cause a positive feedback loop in the 
      amplification of activation of innate and adaptive immunity. Furthermore, 
      manipulation of DCs via toll-like receptor knockout in a murine lupus model leads 
      to alteration in disease severity and survival. Thus, tolerogenic DCs may appear 
      as a potential cell-based therapeutic option in SLE.
CI  - (c) 2014 The Author. International Journal of Rheumatic Diseases published by Asia 
      Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty 
      Ltd.
FAU - Mok, Mo Yin
AU  - Mok MY
AD  - Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen 
      Mary Hospital, The University of Hong Kong, Hong Kong, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141231
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
SB  - IM
MH  - Animals
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/drug effects/*immunology
MH  - Disease Models, Animal
MH  - Female
MH  - Humans
MH  - Immune Tolerance/*physiology
MH  - Immunity, Cellular/physiology
MH  - Lupus Erythematosus, Systemic/*immunology/*therapy
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - Molecular Targeted Therapy/*methods
MH  - Prognosis
MH  - Risk Assessment
MH  - Role
MH  - Treatment Outcome
OTO - NOTNLM
OT  - disease aetiology and pathogenesis - animal models
OT  - disease aetiology and pathogenesis - human
OT  - innate immunity
OT  - systemic lupus erythematous
EDAT- 2015/02/03 06:00
MHDA- 2016/01/06 06:00
CRDT- 2015/02/03 06:00
PHST- 2015/02/03 06:00 [entrez]
PHST- 2015/02/03 06:00 [pubmed]
PHST- 2016/01/06 06:00 [medline]
AID - 10.1111/1756-185X.12532 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2015 Feb;18(2):250-9. doi: 10.1111/1756-185X.12532. Epub 2014 
      Dec 31.